Merck & Co., Inc. has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite looming patent expiry in 2028. MRK has aggressively pursued acquisitions and partnerships, notably with Terns Pharma, Cidara, Verona, and Daiichi Sankyo, to diversify its pipeline. By 2030, I project MRK can offset Keytruda declines with ~$17.35bn in new product revenues, supporting a potential $350bn valuation—~15% above current levels.